European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)

{
  "signal_id": "b8586105-9281-0e44-5a62-d60f1fe52a70",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-21T15:45:00+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/21/3365684/0/en/european-commission-approves-roche-s-susvimo-for-the-treatment-of-neovascular-age-related-macular-degeneration-namd.html",
    "title": "European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)",
    "excerpt": "Basel, 21 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of vision loss in people over the age of 60. 5,6 “The European Commission approval of Susvimo now provides this continuous delivery option to people in Europe with neovascular age-related macular degeneration,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Many nAMD patients are unable to extend their dosing interval beyond every eight weeks, and 40% discontinue treatment within two years. By offering patients continuous delivery through a refillable implant, Susvimo offers a unique alternative to frequent eye injections that can help maintain vision while significantly reducing the treatment burden.” In 2025, Roche was granted a CE mark for its Port Delivery Platform, known as Contivue® in the European Union (EU), which comprises the eye implant that delivers Susvimo and four ancillary devices to initially fill, insert, refill, and remove the implant (if required). 7 Contivue provides continuous delivery of Susvimo directly into the eye. Susvimo has been specifically developed for use with Contivue. Roche is evaluating other molecules in the pipeline that could...",
    "product": "Susvimo",
    "summary": "Roche's drug Susvimo® has been approved by the European Commission for the treatment of neovascular age-related macular degeneration (nAMD) in Europe.",
    "location": "Europe",
    "planning": false,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
    "confidence": 0.95,
    "product_data": {
      "name": "Susvimo",
      "full_text": "Susvimo® (ranibizumab 100 mg/mL solution for injection)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-21T15:45:00Z",
    "location_data": [
      {
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-21",
    "article_sentence": "Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of vision loss in people over the age of 60."
  }
}

curl https://signals.autobound.ai/v1/signals/b8586105-9281-0e44-5a62-d60f1fe52a70 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"roche.com","limit":20}'